The clinicopathologic characteristics of familial and sporadic papillary thyroid carcinoma in Turkish patients

Havva SEZER1*, Mehmet Onur DEMİRKOL2, Dilek YAZICI1, Yersu KAPRAN3, Faruk ALAGÖL1
1Department of Endocrinology and Metabolism, Faculty of Medicine, Koç University, İstanbul, Turkey
2Department of Nuclear Medicine, Faculty of Medicine, Koç University, İstanbul, Turkey
3Department of Pathology, Faculty of Medicine, Koç University, İstanbul, Turkey

1. Introduction
Well differentiated thyroid carcinoma is the most common endocrine related cancer (80%–90% papillary, 10%–15% follicular) [1]. The majority of papillary and follicular thyroid carcinomas are sporadic, but some are inherited (familial or associated with hereditary cancer syndromes) [1]. These inheritable cancers constitute approximately 8% of all nonmedullary thyroid cancers [1]. PTC is the most common histological subtype, followed by FTC follicular variant, follicular thyroid carcinoma, and very rarely seen anaplastic carcinoma [2]. Familial nonmedullary thyroid cancers can be divided into 2 clinicopathological groups. The first group includes several syndromes that are associated with an increased risk of thyroid cancer like Cowden syndrome, familial adenomatous polyposis, Werner syndrome, and Carney complex. These may have an increased risk of benign thyroid disease as well [3]. The second group includes familial syndromes characterized by predominance of PTC, such as pure fPTC, fPTC associated with papillary renal cell carcinoma, and fPTC with multinodular goiter [3]. fPTC can be diagnosed when 2 or more first degree family members are affected with thyroid cancer of follicular cell origin including the index patient with the exclusion of other familial cancer syndromes [4]. When there are 2 affected family members with thyroid cancer, the probability that the affected members have a familial syndrome is reported to be 38% [5]. However, in families with 3 or more affected family members with thyroid cancer, the probability increases to more than 96% [5]. fPTC was first reported in 1955 by Robinson and Orr in monozygotic twins [6]. fPTC is genetically heterogeneous and multigenic between different families [7]. Genes responsible for fPTC have not been identified yet [7]. Nowadays, it is believed that, fPTC is due to a combination of genetic and environmental factors [7].

Background/aim: The aim of this study is to investigate clinicopathologic features of familial papillary thyroid carcinoma (fPTC) and compare them with sporadic papillary thyroid carcinoma (sPTC) in Turkish patients. A retrospective analysis of the papillary thyroid carcinoma (PTC) cases, with or without family history with a follow-up around 10 years was performed.

Materials and methods: A series of patients with fPTC (82 fPTC families with 146 affected individuals) were compared with patients with sPTC (n = 112). The clinicopathologic features [(age, gender, histologic subtype, tumour size, bilaterality, multifocality, extrathyroidal extension (ETE), lymph node metastasis (LNM)] and treatment procedures (lymph node dissection, radioactive iodine ablation), and the outcomes like recurrences in the neck region, distant metastasis, and the need for reoperation were compared between the groups.

Results: When the groups were compared, there was no significant difference in age (P = 0.449), and tumour size (P = 0.898) between familial and sporadic PTC patients. fPTC group had a significantly higher risk of male gender (P=0.001), bilaterality (P = 0.004), multifocality (P = 0.011), LNM (P = 0.013), ETE (P = 0.040), and distant metastasis (P ≤ 0.0001) than the sPTC group. However, recurrence rate was similar between the 2 groups (P = 0.436).

Conclusion: The results of this study confirms a more aggressive nature in fPTC patients, in terms of bilaterality, multifocality, ETE, LNM, and distant metastasis, compared to sPTC patients in Turkish population.

Key words: Familial, sporadic, papillary thyroid cancer

Received: 16.07.2019  •  Accepted/Published Online: 29.01.2020  •  Final Version: 09.04.2020

This work is licensed under a Creative Commons Attribution 4.0 International License.
Most authors agree that fPTC is more aggressive than sPTC. This aggressiveness is characterized by multicentricity, larger tumour size, ETE, vascular invasion, and lymph nodal involvement [4,8–17]. Since there is also contradictory data, it remains controversial [1,18–21].

Turkey is in a region that is with an increased risk of thyroid cancer. Iodine deficiency and being in close proximity to the Chernobyl accident have increased the incidence of thyroid cancer in Turkey [22]. There is no data determining the aggressiveness of fPTC in Turkish patients. Data from some countries as Italy, China, Japan, and Greece indicate increased aggressiveness on the side of fPTC [10,11,23,24]. However, a recent study from Bulgaria did not demonstrate any difference in the aggressiveness of fPTC and sPTC [20].

The aim of this study is to investigate the clinical and pathological features of fPTC and compare them with sPTC in Turkish patients.

2. Materials and methods

All the patients included in this study were diagnosed and were treated for PTC between 2001 and 2015. The study was a retrospective study, and all procedures in this study were approved by our hospital’s ethics committee (Ethical approval number 2015.104.IRB2.041 with a date of 23 June 2015). Follow-up data information was obtained from hospital records. Information about the family history of thyroid cancer was obtained from the patients’ records. Patients with a positive family history were classified as fPTC when at least 2 first degree family members were affected without any other familial cancer syndromes. There were no patients with other familial cancer syndromes in our study population. To determine whether fPTC had aggressive behaviour, the clinical and pathological features such as age at diagnosis, gender, tumour size, histological variant, multifocality, bilaterality, ETE, vascular invasion, LNM, distant metastasis, recurrent disease, and treatment characteristics (central lymph node dissection, remnant ablation) were compared between sPTC and fPTC patients.

This study included a total of 258 patients; 146 patients with fPTC, and aged matched 112 sPTC among patients. All patients of the study had undergone total thyroidecomy. Lateral compartment lymph node dissection was performed in patients with biopsy-proven metastasis. Radioactive iodine (RAI) treatment had been performed according to tumour size of >10 mm and the presence of multifocality, ETE, LNM, and distant metastasis. Thyroid hormone treatment had been initiated after the remnant ablation to decrease serum TSH to subnormal level. In patients treated with total thyroidecomy, measurement of serum thyrogblobulin (Tg), anti-Tg antibodies during therapy with levothyroxine and neck ultrasonography had been performed 6 months after surgery and then annually.

Persistent/recurrent disease was defined:

1) When stimulated Tg exceeded 2 ng/ml in patients who underwent total thyroidecomy
2) Metastatic lymph nodes were detected by neck ultrasound and confirmed by fine-needle aspiration cytology
3) Positive 131-I-whole body screening (WBS)

The median postoperative follow-up duration was 10 years (min: 3 years, max: 17 years).

2.1. Statistical analysis

Statistical analysis was performed with a SPSS software package version 25 (IBM Corp., Armonk, NY, USA). Categorical variables were expressed as number while continuous variables were expressed as mean ± standard deviation. Pearson chi-square (χ²) test was used to compare groups regarding categorical variables. Continuous variables were compared with student t-test. The results were evaluated at P < 0.05 significance level with a 95% confidence interval.

3. Results

The mean age at diagnosis was 43.3 ± 13.7 years in patients of fPTC, and 41.2 ± 10.5 years in patients of sPTC. The male to female ratio was greater in the fPTC group compared to sPTC group (in fPTC group: 46/100, in sPTC group: 20/92) (P = 0.001). The mean tumour diameter was 11.1 ± 7.5 mm in patients of fPTC, and 11.6 ± 7.9 mm in patients of sPTC. There were no significant differences in terms of age at diagnosis (P = 0.449) and tumour size (P = 0.898) between the 2 groups.

fPTC group had a significantly higher risk of bilaterality (P = 0.004), multifocality (P = 0.011), ETE (P = 0.040), LNM (P = 0.013), and distant metastasis (P ≤ 0.0001) than the sPTC group (as shown in Table 1). All of the metastasis were to lung in fPTC patient group. The histological types in each group were comparable (P = 0.817). There were 3 patients with tall cell variant and 3 patients with diffuse sclerosing variant in fPTC group. On the other hand lymphatic and vascular invasion were more prominent in the sPTC group compared to the fPTC group (P ≤ 0.0001, P = 0.011, respectively). fPTC group was more prone to have coexistence with lymphocytic thyroiditis compared with the sPTC group (P ≤ 0.0001).

The number of patients that had RAI ablation therapy were higher in the fPTC group compared to the sPTC group (P = 0.007). The recurrences were at the lymph nodes in the central or lateral regions in both groups. All of the recurrences were treated with reoperations (as central or lateral region dissections). Thus, the reoperation rates indicate the recurrence rates. The recurrence rates were similar between the groups (P = 0.436). There was no mortality in follow up period around 10 years in both of the 2 groups.
The clinicopathological characteristics were also compared according to the number of affected relatives in the familial group (as shown in Table 2). One hundred and forty six fPTC patients represented 82 families. We divided the fPTC patient group into 2 subgroups: 1) 122 patients of the 68 families with fPTC had 2 affected family members, and 24 patients of the 14 families with fPTC had 3 or more affected family members. The mean age at diagnosis was 43.6 ± 14.1 years in patients with 2 affected family members, and 41.4 ± 10.6 years in patients with ≥ 3 affected family members. There were no significant differences in age at diagnosis (P = 0.502) and tumour size (P = 0.104) between the 2 groups. The number of microcarcinomas were more in the group with 2 affected family members compared to ≥ 3 affected family members. The tumour subtype was not different between the groups (P = 0.616). The incidence of multifocality and having LNM were similar between the groups (P = 0.028, P = 0.149, respectively). Vascular invasion and ETE were more prominent in the group of 2 affected family members compared to the group with ≥ 3 affected family members (P = 0.039, P = 0.0001, respectively). The incidence of bilaterality, and distant metastasis in the group with ≥ 3 affected family members were significantly higher than in the group with 2 affected family members (P = 0.036, P = 0.008, respectively). More patients in the group with ≥ 3 affected family members had lymphocytic thyroiditis compared to the other group (P = 0.026). RAI ablation treatment was performed more frequently in the group with 2 affected family members compared to the other group (P = 0.009). Finally the need for reoperation was similar between the groups (P = 0.992).

The sPTC group was compared with the fPTC group of 2 affected family members (as shown in Table 3). The incidence of multifocality (P = 0.003), bilaterality (P = 0.036), ETE (P = 0.026), distant metastasis (P ≤ 0.0001), and lymphocytic thyroiditis (P ≤ 0.0001) in families with 2 affected family members were significantly higher than those of the sPTC group.

When clinicopathological characteristics of the sPTC group was compared with the fPTC group of 3 or more affected family members (as shown in Table 4), ETE was more evident in the sporadic group (P = 0.039) and distant metastasis was more in the fPTC group (P ≤ 0.0001). RAI was given more in the sPTC group compared to the fPTC group (P = 0.005).

#### Table 1. Clinicopathological characteristics and prognostic outcomes of the patients. Familial versus sporadic group.

|                  | fPTC (n = 146) | sPTC (n = 112) | P-value |
|------------------|----------------|----------------|---------|
| Age ≥ 45 years   | 62 (42.5%)     | 36 (32.1%)     | 0.449   |
| Age < 45 years   | 84 (57.5%)     | 76 (67.9%)     |         |
| Tumour size > 10 mm | 74 (50.7%)   | 59 (52.7%)     | 0.898   |
| Tumour size ≤ 10 mm | 72 (49.3%) | 53 (47.3%)     |         |
| Male             | 46 (31.5%)     | 20 (17.9%)     | 0.001   |
| Female           | 100 (68.5%)    | 92 (82.1%)     |         |
| Multifocality    | 71 (48.6%)     | 39 (34.8%)     | 0.011   |
| Bilaterality     | 46 (31.5%)     | 29 (25.8%)     | 0.004   |
| Classical variant| 83 (56.8%)     | 66 (59.0%)     | 0.817   |
| Nonclassical variant | 63 (43.2%) | 46 (41.0%)     |         |
| Lymph node metastasis | 34 (23.2%) | 23 (20.5%)     | 0.013   |
| Lymphatic invasion | 13 (8.9%)     | 33 (29.4%)     | <0.0001 |
| Vascular invasion | 12 (8.2%)     | 12 (10.7%)     | 0.111   |
| ETE              | 28 (19.1%)     | 21 (18.7%)     | 0.040   |
| Distant metastasis| 5 (3.4%)      | 0 (0%)         | <0.0001 |
| Lymphocytic thyroiditis | 71 (48.6%) | 41 (36.6%)     | <0.0001 |
| RAI ablation     | 110 (75.3%)    | 78 (69.6%)     | 0.007   |
| Recurrence/re-operation | 19 (13.0%) | 11 (9.8%)      | 0.436   |

ETE: Extrathyroidal extension, RAI: Radioactive iodine.
When the patients with the classical subtype of PTC in both groups were compared in terms of the clinopathological characteristics (as shown in Table 5), multifocality (P = 0.046), ETE (P < 0.0001), and the presence of lymphocytic thyroiditis (<0.0001) were more evident in the fPTC. Lymphatic invasion was more prominent in the sPTC group (P = 0.041).

When the patients with the nonclassical subtype of PTC in both groups were compared in terms of the clinopathological characteristics (as shown in Table 6), distant metastasis (P < 0.0001), and the presence of lymphocytic thyroiditis (<0.0001) were more evident in the fPTC group.

4. Discussion

The clinical behaviour of fPTC is still controversial. Some studies found that the biological behaviour of fPTC tends to be more aggressive than sPTC [8,23,25], but others have claimed that there are no differences between the 2 groups [18–21,26]. In our study, fPTC and sPTC were similar based on recurrence rate, but some differences were observed in the clinopathological features. Multifocality, bilaterality, ETE, LNM, and distant metastasis were significantly higher in the fPTC patients compared to the sPTC patients. To our knowledge, this is the first study to investigate the clinocopathological characteristics of fPTC in Turkish patients.

Age is the strongest predictor of survival in nonmedullary thyroid carcinoma. Some groups report a lower age at diagnosis in familial cases [1,13]. However, we did not report a significant difference in age between familial and sporadic cases, like many others [3,8–12]. This may be related to missed screening following the diagnosis in the other family members. Males seem to be predominant in some series as ours [3], whereas there are others showing similar rates in both genders [1,9,19].

Considering the characteristics of the tumour, the tumour size was generally similar in fPTC cases compared to sPTC cases [4,9,12]. Our findings supported this. However, a study from China reported larger tumour size in familial cases [11]. Multifocality was increased in the familial cases in our study compared to the sporadic ones. There is conflicting data in the literature with regards to multifocality in fPTC patients [3,9,10,20].

ETE and LNM are important features of aggressiveness. Our findings revealed increased ETE and LNM in fPTC patients compared to sPTC patients. Many studies reported a significantly higher rate of ETE and LNM in fPTC with regards to sPTC [8–11,13]. In contrast to these

|                        | Family = 2 (n = 122) | Family ≥ 3 (n = 24) | P-value |
|------------------------|----------------------|---------------------|---------|
| Age ≥ 45 years         | 52 (42.7%)           | 10 (41.7%)          | 0.502   |
| Age < 45 years         | 70 (57.3%)           | 14 (58.3%)          |         |
| Tumour size > 10 mm    | 56 (45.9%)           | 18 (75.0%)          | 0.104   |
| Tumour size ≤ 10 mm    | 66 (54.1%)           | 6 (25.0%)           |         |
| Female                 | 83 (68.0%)           | 17 (70.8%)          | 0.061   |
| Male                   | 39 (32.0%)           | 7 (29.2%)           |         |
| Multifocality          | 59 (48.3%)           | 12 (50.0%)          | 0.208   |
| Bilaterality           | 37 (30.3%)           | 9 (37.5%)           | 0.036   |
| Classical variant      | 70 (57.3%)           | 13 (54.1%)          | 0.616   |
| Nonclassical variant   | 52 (42.7%)           | 11 (45.9%)          |         |
| Lymph node metastasis  | 26 (21.3%)           | 8 (33.3%)           | 0.149   |
| Lymphatic invasion     | 10 (8.2%)            | 3 (12.5%)           | 0.013   |
| Vascular invasion      | 11 (9.0%)            | 1 (4.2%)            | 0.039   |
| ETE                    | 25 (20.4%)           | 3 (12.5%)           | 0.0001  |
| Distant metastasis     | 3 (2.5%)             | 2 (8.3%)            | 0.008   |
| Lymphocytic thyroiditis| 58 (47.5%)           | 13 (54.1%)          | 0.026   |
| RAI ablation           | 95 (77.8%)           | 15 (62.5%)          | 0.009   |
| Recurrence/re-operation| 16 (13.1%)           | 3 (12.5%)           | 0.992   |

ETE: Extrathyroidal extension, RAI: Radioactive iodine.
findings, some authors have found no association between family history and nodal disease [1,12,20,23].

Previous reports on fPTC indicated that recurrence risk was associated with size, number of foci, subtype of the tumour, ETE, vascular invasion and metastasis [8]. There is data showing the diagnosis of PTC in family members to be solely a risk for recurrence compared to sPTC [4,9,11–13,16,17]. This data has not been included in risk stratification yet. Other authors reported no differences in the clinical behaviour of sporadic and familial PTCs [18–21]. In our study, although tendency to multifocality, increased rate of ETE, LNM, and distant metastasis were seen in the fPTC cases. Our comparative analysis between familial and sporadic PTC showed similar recurrence rate. We used American Thyroid Association (ATA) Guideline 2015 to determine the indication for RAI therapy. Having LNM, distant metastasis and ETE were higher in familial group than sporadic group. Thus, the tumours in this group had more risk indicators for RAI therapy. As a result, more patients in the familial group has got RAI and this might have been an explanation why the recurrence and reoperation rates were similar between the familial and sporadic groups.

The subtype of the tumour is an important factor affecting the risk of recurrence. Our study population consisted mostly of classical subtype of PTC. Considering the nonclassical variants, mostly were nonaggressive types. When the analysis of classical and nonclassical types were made separately, features like distant metastasis were more evident in the familial group regardless of the tumour subtype.

How the number of affected members is associated with tumour aggressiveness remains unknown. Some studies showed that fPTC with 3 or more affected members have more aggressive features than with 2 affected members [9,11,16,17,27]. However, there is also contradictory data [14,15,23]. In this study, we found that patients in the 3 affected members group were more likely to have distant metastasis and bilateral growth. The recurrence rate of patients with 2 affected family members did not differ from with 3 or more affected family members in our analysis. Our findings were in agreement with several reports [13,16]. However, the numbers of patients with 3 or more affected members were few in our study population to make a definitive conclusion. When the comparison of patients with 3 or more affected family members was made with the sPTC group, ETE was more evident in the sporadic group while distant metastasis was more evident in the fPTC group. Larger patient groups would be needed to elucidate this point.

Table 3. Clinicopathological characteristics and prognostic factors of sPTC versus fPTC with 2 affected members.

| Clinicopathological Characteristics | Family = 2 (n = 122) | sPTC (n = 112) | P-value |
|-------------------------------------|-----------------------|---------------|--------|
| Age ≥ 45 years                      | 52 (42.7%)            | 36 (32.1%)    | 0.449  |
| Age < 45 years                      | 70 (57.3%)            | 76 (67.9%)    |        |
| Tumour size > 10 mm                 | 56 (45.9%)            | 59 (52.7%)    | 0.681  |
| Tumour size ≤ 10 mm                 | 66 (54.1%)            | 53 (47.3%)    |        |
| Female                              | 83 (68.0%)            | 92 (82.1%)    | 0.019  |
| Male                                | 39 (32.0%)            | 20 (17.9%)    |        |
| Multifocality                       | 59 (48.3%)            | 39 (34.8%)    | 0.003  |
| Bilaterality                        | 37 (30.3%)            | 29 (25.8%)    | 0.036  |
| Classical variant                   | 70 (57.3%)            | 66 (59.0%)    | 0.788  |
| Nonclassical variant                | 52 (42.7%)            | 46 (41.0%)    |        |
| Lymph node metastasis               | 26 (21.3%)            | 23 (20.5%)    | 0.546  |
| Lymphatic invasion                  | 10 (8.2%)             | 33 (29.4%)    | <0.0001|
| Vascular invasion                   | 11 (9.0%)             | 12 (10.7%)    | 0.566  |
| ETE                                 | 25 (20.4%)            | 21 (18.7%)    | 0.026  |
| Distant metastasis                  | 3 (2.5%)              | 0 (0%)        | <0.0001|
| Lymphocytic thyroiditis             | 58 (47.5%)            | 41 (36.6%)    | <0.0001|
| RAI ablation                        | 95 (77.8%)            | 78 (69.6%)    | 0.005  |
| Recurrence/re-operation             | 16 (13.1%)            | 11 (9.8%)     | 0.829  |

ETE: Extrathyroidal extension, RAI: Radioactive iodine.
Table 4. Clinicopathological characteristics and prognostic factors of sPTC versus fPTC with 3 or more affected members.

|                        | Family ≥ 3 (n = 24) | SPTC (112) | P-value |
|------------------------|---------------------|------------|---------|
| Age ≥ 45 years         | 10 (41.7%)          | 36 (32.1%) | 0.800   |
| Age < 45 years         | 14 (58.3%)          | 76 (67.9%) |         |
| Tumour size > 10 mm    | 18 (75.0%)          | 59 (52.7%) | 0.991   |
| Tumour size ≤ 10 mm    | 6 (25.0%)           | 53 (47.3%) |         |
| Female                 | 17 (70.8%)          | 92 (82.1%) | 0.076   |
| Male                   | 7 (29.2%)           | 20 (17.9%) |         |
| Multifocality          | 12 (50.0%)          | 39 (34.8%) | 0.290   |
| Bilaterality           | 9 (37.5%)           | 29 (25.8%) | 0.384   |
| Classical variant      | 13 (54.1%)          | 66 (59.0%) | 0.252   |
| Nonclassical variant   | 11 (45.9%)          | 46 (41.0%) |         |
| Lymph node metastasis  | 8 (33.3%)           | 23 (20.5%) | 0.254   |
| Lymphatic invasion     | 3 (12.5%)           | 33 (29.4%) | 0.079   |
| Vascular invasion      | 1 (4.2%)            | 12 (10.7%) | 0.407   |
| ETE                    | 3 (12.5%)           | 21 (18.7%) | 0.039   |
| Distant metastasis     | 2 (8.3%)            | 0 (0%)     | <0.0001 |
| Lymphocytic thyroiditis| 13 (54.1%)          | 41 (36.6%) | 0.022   |
| RAI ablation           | 15 (62.5%)          | 78 (69.6%) | 0.005   |
| Recurrence/re-operation| 3 (12.5%)           | 11 (9.8%)  | 0.966   |

ETE: Extrathyroidal extension, RAI: Radioactive iodine.

Table 5. Clinicopathological characteristics and prognostic outcomes of the patients with classical variant. Familial versus sporadic group.

|                        | fPTC (n = 83) | sPTC (n = 66) | P-value |
|------------------------|--------------|--------------|---------|
| Age ≥ 45 years         | 31 (37.4%)   | 20 (30.3%)   | 0.742   |
| Age < 45 years         | 52 (62.6%)   | 46 (69.7%)   |         |
| Tumour size > 10 mm    | 36 (43.4%)   | 34 (51.5%)   | 0.743   |
| Tumour size ≤ 10 mm    | 47 (56.6%)   | 32 (48.5%)   |         |
| Female                 | 55 (66.3%)   | 53 (80.3%)   | 0.492   |
| Male                   | 28 (33.7%)   | 13 (19.7%)   |         |
| Multifocality          | 46 (55.4%)   | 14 (21.2%)   | 0.046   |
| Bilaterality           | 29 (34.9%)   | 13 (19.6%)   | 0.279   |
| Lymph node metastasis  | 22 (26.5%)   | 20 (30.3%)   | 0.458   |
| Lymphatic invasion     | 10 (12.0%)   | 25 (37.8%)   | 0.041   |
| Vascular invasion      | 9 (10.8%)    | 7 (10.6%)    | 0.935   |
| ETE                    | 19 (22.8%)   | 12 (18.1%)   | <0.0001 |
| Distant metastasis     | 2 (2.4%)     | 0 (0%)       | <0.0001 |
| Lymphocytic thyroiditis| 46 (55.4%)   | 31 (46.9%)   | <0.0001 |
| RAI ablation           | 69 (83.1%)   | 51 (77.2%)   | 0.851   |
| Recurrence/re-operation| 10 (12.0%)   | 2 (3.0%)     | 0.467   |

ETE: Extrathyroidal extension, RAI: Radioactive iodine.
The optimal treatment for patients with a diagnosis of fPTC is unknown. The majority of authors recommend that patients should undergo total thyroidectomy [23]. In addition, considering that the rate of LNM was higher in familial disease than in sporadic disease, some authors recommend prophylactic central neck dissection [17]. However, not all groups agree [28]. The role of RAI treatment is also currently unclear. In a study from Brazil, with tumours of ≤ 20 mm, with nonaggressive histology, no ETE, no important lymph node involvement, and no evidence of persistent disease after surgery, none of the patients received RAI [28]. No case of recurrence was detected [28]. There are groups that recommend total thyroidectomy followed by postoperative RAI therapy, regardless of tumour size [29]. In our analysis, all patients had total thyroidectomy and the majority of the fPTC cases had received RAI therapy. The indication for RAI treatment were determined by tumour size of >10 mm and the presence of multifocality, ETE, LNM, and distant metastasis. Since all these features were present in the tumours in the fPTC group, RAI therapy had been applied in all of them.

There are many studies from different countries regarding the character of fPTC. A single centre study in China found that patients with fPTC were more likely to present as large tumours, with multifocality, local invasion, and LNM [11]. In a Japanese study, Ito et al. showed that the occurrence of multifocality, and recurrence rate were significantly higher in their fPTC patients. However, LNM, local invasion, and disease-free survival rate did not significantly differ between familial and sporadic patient groups [23]. A study with 2 different cohorts from Italy and Greece demonstrated that tumours of fPTC patients were more frequently multifocal, tended to have higher recurrence rate, and had worse outcomes when compared with sPTC patients [24]. Another study from Italy also confirmed these findings that fPTC had increased aggressiveness at diagnosis, a higher rate of persistent/recurrent disease, and mortality [10]. However, in Bulgaria, Vidinov et al. showed a statistically significant difference only in tumour size between the familial and sporadic groups [20]. To our knowledge, this is the first study evaluating the clinicopathological and prognostic features of the fPTC patients in Turkish population. The mean postoperative follow-up duration was about 10 years. According to results of our study, it may be that fPTC has more aggressive behaviour with multifocal disease, bilateral disease, extrathyroidal spread, a higher rate of LNM, and distant metastasis. We demonstrated that the recurrence rate of patients with fPTC was the same as patients with sPTC in Turkish population. The unique part of our study is that although the tumours seemed to be more aggressive in the fPTC group compared to the sPTC group, probably the increased application of

| clinicopathological characteristics | fPTC (n = 63) | sPTC (n = 46) | P-value |
|-----------------------------------|--------------|--------------|---------|
| Age ≥ 45 years                    | 31 (49.2%)   | 16 (34.8%)   | 0.163   |
| Age < 45 years                    | 32 (50.8%)   | 30 (65.2%)   |         |
| Tumour size > 10 mm               | 38 (60.3%)   | 25 (54.3%)   | 0.566   |
| Tumour size ≤ 10 mm               | 25 (39.7%)   | 21 (45.7%)   |         |
| Female                            | 45 (71.4%)   | 39 (84.7%)   | 0.964   |
| Male                              | 18 (28.6%)   | 7 (15.3%)    |         |
| Multifocality                     | 25 (39.6%)   | 25 (54.3%)   | 0.468   |
| Bilaterality                      | 17 (26.9%)   | 16 (34.7%)   | 0.416   |
| Lymph node metastasis             | 12 (19.0%)   | 3 (6.5%)     | 0.719   |
| Lymphatic invasion                | 3 (4.7%)     | 8 (17.3%)    | 0.749   |
| Vascular invasion                 | 3 (4.7%)     | 5 (10.8%)    | 0.162   |
| ETE                               | 9 (14.2%)    | 9 (19.6%)    | 0.057   |
| Distant metastasis                | 3 (4.7%)     | 0 (0%)       | <0.0001 |
| Lymphocytic thyroiditis           | 25 (39.6%)   | 10 (21.7%)   | <0.0001 |
| RAI ablation                      | 41 (65.0%)   | 27 (58.7%)   | 0.235   |
| Recurrence/re-operation           | 9 (14.2%)    | 9 (19.5%)    | 0.057   |

ETE: Extrathyroidal extension, RAI: Radioactive iodine.
RAI decreased the recurrences. It may also have regional implications, although at least data from countries close by expressed more aggressive features in the familial forms as in our cases.

The study included patients who had their surgeries between the dates of 2001 and 2015. Mostly the choices of the operations were usually total thyroidectomy. Recently the recommendations of most of the societies are in favour of less invasive surgeries. The approach might have been different if the surgeries were conducted today, but there is no data in the guidelines regarding the familial cases. By the less invasive surgeries and probably less incline towards RAI therapy, it would probably be easier to observe the recurrence rates.

The study had some limitations. Firstly, the follow-up period had a very great range, from 3 years to 17 years. Given the indolent course of the PTC, this might lead to a heterogeneous follow-up periods of the patients to evaluate the outcomes. The second limitation was retrospective study design.

In conclusion; our study showed that family history was an important risk factor for more aggressive characteristics with high incidence of multifocality, bilaterality, ETE, LNM, and a higher rate of distant metastasis in Turkish patients with PTC. However, recurrence rates did not differ between the familial and sporadic groups.

Acknowledgement/Disclaimers/Conflict of Interest
Conflict of Interest: The authors declare that there is no conflict of interest for this study both for financial and publication sides.

Fundings: Not applicable.
Consent: All of our patients permitted us to use their medical information.

References

1. Moses W, Weng J, Kebebew E. Prevalence, clinicopathologic features, and somatic genetic mutation profile in familial versus sporadic nonmedullary thyroid cancer. Thyroid 2011; 21 (4): 367-371. doi: 10.1089/thy.2010.0256
2. Vriens MR, Suh I, Moses W, Kebebew E. Clinical features and genetic predisposition to hereditary nonmedullary thyroid cancer. Thyroid 2009; 19 (12): 1343-1349. doi: 10.1089/thy.2009.1607
3. Griffith CC, Seethala RR. Familial nonmedullary thyroid cancer: an update on the genetic and pathologic features. Diagnostic Histopathology 2016; 22 (3): 101-107. doi: 10.1016/j.dhmp.2016.02.005
4. Uchino S, Noguchi S, Kawamoto H, Yamashita H, Watanabe S et al. Familial nonmedullary thyroid carcinoma characterized by multifocality and a high recurrence rate in a large study population. World Journal of Surgery 2002; 26 (8): 897-902. doi: 10.1007/s00268-002-6615-y
5. Charkes ND. On the prevalence of familial nonmedullary thyroid cancer in multiply affected kindreds. Thyroid 2006; 16 (2): 181-186. doi: 10.1089/thy.2006.16.181
6. Robinson DW, Orr TG. Carcinoma of the thyroid and other diseases of the thyroid in identical twins. American Medical Association Archives of Surgery 1955; 70 (6): 923-928. doi:10.1001/archsurg.1955.01270120131015
7. Rowland KJ, Moley JF. Hereditary thyroid cancer syndromes and genetic testing. Journal of Surgical Oncology 2015; 111 (1): 51-60. doi:10.1002/jso.23769
8. Zhang Q, Yang S, Meng XY, Chen G, Pang RZ. Clinical analysis of familial nonmedullary thyroid carcinoma. World Journal of Surgery 2016; 40 (3): 570-573. doi: 10.1007/s00268-015-3342-8
9. McDonal DJ, Driedger AA, Garcia BM, Van Uum SH, Rachinsky I et al. Familial papillary thyroid carcinoma: a retrospective analysis. Journal of Oncology 2011; 2011 (Article ID 948786): 8 pages. doi: 10.1155/2011/948786
10. Tavarelli M, Russo M, Terranova R, Scollo C, Spadaro A et al. Familial nonmedullary thyroid cancer represents an independent risk factor for increased cancer aggressiveness: a Retrospective analysis of 74 families. Frontiers in Endocrinology 2015; 6: 117. doi: 10.3389/fendo.2015.00117
11. Lei S, Wang D, Ge J, Liu H, Zhao D et al. Single center study of familial papillary thyroid cancer in China: surgical considerations. World Journal of Surgery 2015; 13: 115. doi:10.1186/s12957-015-0519-4
12. Lee YM, Yoon JH, Yi O, Sung TY, Chung TW et al. Familial history of nonmedullary thyroid cancer is an independent prognostic factor for tumor recurrence in younger patients with conventional papillary thyroid carcinoma. Journal of Surgical Oncology 2014; 109 (2): 168-173. doi: 10.1002/jso.23447
13. Mazeh H, Benavidez J, Poehls JL, Youngwirth L, Chen H et al. In patients with thyroid cancer of follicular cell origin, a family history of nonmedullary thyroid cancer in one first-degree relative is associated with more aggressive disease. Thyroid 2012; 22 (1): 3-8. doi: 10.1089/thy.2011.0192
14. Park YJ, Ahn HY, Choi HS, Kim KW, Park DJ et al. The long-term outcomes of the second generation of familial nonmedullary thyroid carcinoma are more aggressive than sporadic cases. Thyroid 2012; 22 (4): 356-362. doi: 10.1089/thy.2011.0163
15. Sung TY, Lee YM, Yoon JH, Chung KW, Hong SJ. Surgical management of familial papillary thyroid microcarcinoma: a single institution study of 94 cases. World Journal of Surgery 2015; 39 (8): 1930-1935. doi: 10.1007/s00268-015-3064-y
16. Zhang YB, Wang XX, Zhang XW, Li ZJ, Liu J et al. Familial nonmedullary thyroid carcinoma: a retrospective analysis of 117 families. Chinese Medical Journal 2018; 131 (4): 395-401. doi: 10.4103/0366-6999.225054

367
17. Triponez F, Wong M, Sturgeon C, Caron N, Ginzinger DG et al. Does familial nonmedullary thyroid cancer adversely affect survival? World Journal of Surgery 2006; 30 (5): 787-793. doi: 10.1007/s00268-005-0398-x

18. Maxwell EL, Hall FT, Freeman JL. Familial nonmedullary thyroid cancer: a matched-case control study. Laryngoscope 2004; 114 (12): 2182-2186. doi: 10.1097/01.mlg.0000149454.91005.65

19. Robenshtok E, Tzvetov G, Grozinsky-Glasberg S, Sharaga-Slutsky I, Weinstein R et al. Clinical characteristics and outcome of familial nonmedullary thyroid cancer: a retrospective controlled study. Thyroid 2011; 21 (1): 43-48. doi: 10.1089/thy.2009.0406

20. Vidinov K, Nikolova D. Familial papillary thyroid carcinoma: a retrospective analysis in a sample of the Bulgarian population for a 10-Year period. Endocrine Pathology 2017; 28 (1): 54-59. doi: 10.1007/s12022-016-9456-1

21. Lee J, Song Y, Soh EY. Central lymph node metastasis is an important prognostic factor in patients with papillary thyroid microcarcinoma. Journal of Korean Medical Science 2014; 29 (1): 48-52. doi: 10.3346/jkms.2014.29.1.48

22. Ozdemir D, Dagdelen S, Kiratli P, Tuncel M, Erbas B et al. Changing clinical characteristics of thyroid carcinoma at a single center from Turkey: before and after Chernobyl disaster. Minerva Endocrinologica 2012; 37 (3): 267-274.

23. Ito Y, Kakudo K, Hirokawa M, Fukushima M, Yabuta T et al. Biological behavior and prognosis of familial papillary thyroid carcinoma. Surgery 2009; 145 (1): 100-105. doi: 10.1016/j.surg.2008.08.004

24. Capezzone M, Marchisotta S, Cantara S, Busonero G, Brilli L et al. Familial nonmedullary thyroid carcinoma displays the features of clinical anticipation suggestive of distinct biological entity. Endocrine-Related Cancer 2008; 15 (4): 1073-1081. doi: 10.1677/ERC-08-0080

25. Kraimps JL, Bouin-Pineau MH, Amati P, Mothes D, Bonneau D et al. Familial papillary carcinoma of the thyroid. Surgery 1997; 121 (6): 715-718. doi: 10.1016/S0039-6060(97)90063-5

26. Ito Y, Fukushima M, Yabuta T, Inoue H, Uruno T et al. Prevalence and prognosis of familial follicular thyroid carcinoma. Endocrine Journal 2008; 55 (5): 847-852. doi: 10.1507/endocrj.K08E-057

27. Nixon IJ, Suarez C, Simo R, Sanabria A, Angelos P et al. The impact of family history on nonmedullary thyroid cancer. European Journal of Surgical Oncology 2016; 42 (10): 1455-1463. doi: 10.1016/j.ejso.2016.08.006

28. Rosario PW, Calsolari MR. Should a family history of papillary thyroid carcinoma indicate more aggressive therapy in patients with this tumor? Arquivos Brasileiros de Endocrinologia & Metabolologia 2014; 58 (8): 812-816. doi: 10.1590/0004-2730000003350

29. Navas-Carrillo D, Rios A, Rodriguez JM, Parrilla P, Orenes-Pinero E. Familial nonmedullary thyroid cancer: screening, clinical, molecular and genetic finding. Biochimica et Biophysica Acta 2014; 1846 (2): 468-476. doi: 10.1016/j.bbcan.2014.09.002